tislelizumab
Showing 1 - 25 of 139
Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)
Recruiting
- Unresectable Hepatocellular Carcinoma
- D-TACE
- +3 more
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Oct 14, 2022
Recurrent Hepatocellular Carcinoma Trial in Guangzhou (Tislelizumab, Tislelizumab combined with Levatinib)
Recruiting
- Recurrent Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab combined with Levatinib
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Mar 31, 2022
Immunotherapy Trial (Tislelizumab, Capecitabine, oxaliplatin)
Not yet recruiting
- Immunotherapy
- Tislelizumab
- +4 more
- (no location specified)
Jul 28, 2022
Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)
Recruiting
- Esophageal Squamous Cell Carcinoma
- +2 more
- Tislelizumab
- +3 more
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Institute & Hospital
May 24, 2022
Nasopharyngeal Carcinoma Trial in Beijing (Tislelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Tislelizumab
-
Beijing, Beijing, ChinaNational Cancer Center /National Clinical Research Center for Ca
Jul 4, 2022
Esophageal Cancer Trial (Tislelizumab, Radiation, Paclitaxel)
Not yet recruiting
- Esophageal Cancer
- Tislelizumab
- +3 more
- (no location specified)
Nov 18, 2022
Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)
Recruiting
- Stage III Non-small Cell Lung Cancer
- Neoadjuvant chemo-immunotherapy
- +5 more
-
Guangzhou, ChinaSun Yat-sen University
Jul 19, 2022
Pancreatic Tumors Trial (Tislelizumab)
Not yet recruiting
- Pancreatic Neoplasms
- Tislelizumab
- (no location specified)
Dec 26, 2022
Non Small Cell Lung Cancer Trial (Tislelizumab, Ociperlimab, LBL-007)
Not yet recruiting
- Non Small Cell Lung Cancer
- Tislelizumab
- +2 more
- (no location specified)
Jan 30, 2023
Lung Cancer, Small Cell Trial in Hangzhou (Tislelizumab, Sitravatinib)
Recruiting
- Lung Cancer, Small Cell
- Tislelizumab
- Sitravatinib
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
May 13, 2022
Melanoma Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Not yet recruiting
- Melanoma
- Tislelizumab
- +2 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 4, 2022
Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)
Not yet recruiting
- Immunotherapy Esophagus Cancer
- Tislelizumab
- +3 more
- (no location specified)
Aug 24, 2022
Lymphoma Trial (Tislelizumab)
Not yet recruiting
- Lymphoma
- Tislelizumab
- (no location specified)
Jul 28, 2022
Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)
Not yet recruiting
- Metastatic Cervical Cancer
- Tislelizumab
- Sitravatinib
- (no location specified)
Jan 31, 2023
Head Neck Cancer Trial in Chengdu, Tianjin (Tislelizumab, Pulse radiation)
Recruiting
- Head and Neck Cancer
- Tislelizumab
- Pulse radiation
-
Chengdu, Sichuan, China
- +1 more
Oct 25, 2022
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma Trial in Nanjing (Tislelizumab, 5-FU, cis Platinum)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Locally Advanced Carcinoma
- Tislelizumab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Jul 19, 2022
Cervical Cancer Trial in Nanning (tislelizumab, concurrent chemoradiotherapy)
Not yet recruiting
- Cervical Cancer
- tislelizumab
- concurrent chemoradiotherapy
-
Nanning, Guangxi, ChinaFirst Affiliated Hospital of Guangxi Medical University
Aug 22, 2022
Carcinoma, Hepatocellular, Liver Cell Carcinoma Trial in New Brunswick (Tislelizumab)
Not yet recruiting
- Carcinoma, Hepatocellular
- Liver Cell Carcinoma
- Tislelizumab
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
May 4, 2022
Head and Neck Squamous Cell Carcinoma Trial (Nab-paclitaxel, Cisplatin, Tislelizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Nab-paclitaxel
- +3 more
- (no location specified)
Aug 23, 2022
Pancreatic Cancer Trial in Baltimore (Tislelizumab, SX-682)
Not yet recruiting
- Pancreatic Cancer
- Tislelizumab
- SX-682
-
Baltimore, MarylandJohns Hopkins SKCCC
Jan 23, 2023
Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tislelizumab
- +4 more
-
Wuhan, Hubei, China
- +2 more
Jan 16, 2023
NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),
Recruiting
- NSCLC, Stage III
- Tislelizumab
- +2 more
-
Beijing, Beijing, ChinaBeijing Tsinghua Chang Gung Hospital
Nov 4, 2022
Uterine Cervical Tumors Trial in Nanning (Tislelizumab, DDP synchronous with radiotherapy)
Recruiting
- Uterine Cervical Neoplasms
- Tislelizumab
- DDP synchronous with radiotherapy
-
Nanning, Guangxi, ChinaFirst Affiliated Hospital of Guangxi Medical University
Oct 19, 2022
Advanced Non-small-cell Lung Cancer Trial in Fuzhou (Tislelizumab)
Enrolling by invitation
- Advanced Non-small-cell Lung Cancer
- Tislelizumab
-
Fuzhou, Fujian, ChinaFujian cancer hospital
Jan 13, 2022
Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)
Active, not recruiting
- Muscle Invasive Bladder Cancer
- Urothelial Carcinoma
- Tislelizumab
- Nab paclitaxel
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Jun 8, 2022